Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Same author

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2012

Same author

Human plasma-derived concentrates: preventing thrombosis and controlling haemorrhage.

Haemophilia : the official journal of the World Federation of Hemophilia·2010

Same author

The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.

Haemophilia : the official journal of the World Federation of Hemophilia·2009

Same author

Linking the world with training and research for improving haemophilia care.

Haemophilia : the official journal of the World Federation of Hemophilia·2008

Same author

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.

Haemophilia : the official journal of the World Federation of Hemophilia·2008

Search research articles

Related Experiment Video

Updated: Jul 18, 2026

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs

Published on: February 2, 2024

Urgent inhibitor issues: targets for expanded research.

¹Gulf States Hemophilia and Thrombophilia Center, The University of Texas Health Science Center, Houston, TX 77030, USA. keith.hoots@uth.tmc.edu

Haemophilia : the Official Journal of the World Federation of Hemophilia

|November 25, 2006

Summary

Immune tolerance induction eliminates high-responding inhibitors in severe factor VIII deficiency, but residual morbidity remains. Further research is crucial for understanding haemophilic inhibitor development and improving patient outcomes.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Experiment Videos

Last Updated: Jul 18, 2026

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs

Published on: February 2, 2024

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Area of Science:

Hematology
Immunology
Clinical Research

Background:

Despite successful immune tolerance induction, significant morbidity persists in patients with severe factor VIII deficiency and high-responding inhibitors.
There is a critical need to deepen the understanding of the mechanisms underlying the development of inhibitors in hemophilia.

Purpose of the Study:

To identify key areas for future research in hemophilic inhibitor development.
To address the residual morbidity and unmet needs in patients with severe factor VIII deficiency.

Main Methods:

The article identifies four critical research needs based on current knowledge gaps.
It reviews existing challenges in immune tolerance induction and treatment of hemophilic patients.

Main Results:

Four key research areas are highlighted: differential antigenicity of clotting factor concentrates (CFCs), influences on inhibitor development, role of immune tolerance strategies, and alternative hemorrhage management.
Current CFCs may possess differential antigenicity, impacting immunogenicity and inhibitor development.

Conclusions:

Focused research is essential to elucidate the pathogenesis of hemophilic inhibitor development.
Advancements are needed in understanding CFC immunogenicity, host-environmental factors, immune tolerance, and hemorrhage management to improve care for hemophilic patients.